| ID | 1121 |
| Name of the vaccine | Zyvac TCV |
| Microbe | Bacteria |
| Disease name | Typhoid |
| Name of bacteria | Salmonella typhi |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 6 months to 45 years |
| Description of the vaccine | Purified Vi polysaccharide tetanus toxoid conjugate typhoid vaccine (Vi-TT). |
| Name of the manufacturer | Cadila Healthcare Ltd |
| Name of the manufacturing country | India |
| Year of manufacture | 2017 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram negative bacteria. |
| Efficacy | The seroconversion rate among ZyVac-TCV recipients was 94.8%. |
| Vaccine formulation | Liquid |
| Dosage | Two doses, second dose is given 3 years of first dose. |
| Mechanism of action | The tetanus toxoid acts as conjugation protein and it helps the immune system to recognize the antigens more effectively. |
| Route of administration | Intramuscular |
| Indications | Active immunization to prevent typhoid fever. |
| Export | Marketing authorization only in India |
| Approval | Licensed in India |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Mild to moderate fever, injection site pain and swelling, irritability, headache, lose motions, vomiting. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | 32134011, 32725225 |
| Clinical trial number | NA |
| Reference | https://drbhole.com/zyvac-tcv |
| Other name | NA |
| Additional Links | NA
|